Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

Inclusion Criteria: * Patient included in the main EMPASHOCK study * Patient has signed a consent form for the ancillary study * Patient is over 18 years old * Hospitalized in the Intensive Care Unit for cardiogenic shock\* * Has been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock\*\* * Patient has the ability to take tablets orally * Person is affiliated with or a beneficiary of a social security system Exclusion Criteria: * • GFR \< 20 ml/min/1.73m² * Chronic dialysis * Patient on SGLT2 inhibitors prior to ICU admission * Known allergy to SGLT2 inhibitors or any of their excipients (in particular, patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome). * Patient on lithium * Patient with type 1 diabetes * Patient in shock due to another cause or moribund patient (IGS 2 \> 90) * Cardiogenic shock cases excluded in the EMPASHOCK study: a. Heart transplant recipient or on a transplant list. b. Peripartum, adrenergic, valvular, restrictive, or post-embolic cardiomyopathy. c. Related to cardiotropic drug intoxication. d. Secondary to cardiac arrest where the patient remains comatose before inclusion. * Woman of childbearing age without effective contraception * Person referred to in Articles 10, 31, 32, 33, and 34 of EU Regulation 536/2014, specifically: * Pregnant woman, woman in labor, or breastfeeding mother * Minor person (not emancipated) * Adult person subject to a legal protection measure (guardianship, curatorship, legal safeguard)